The global demand for Cancer Monoclonal Antibodies Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.
In cancer, some cells grow out of control and spread to other parts of the body. Cancer can start in practically any part of the body. Antibodies are key cancer therapeutic agents. Cancer monoclonal antibodies are laboratory-created molecules that act as substitute antibodies to improve, repair, or replicate the immune system's invasion of cancer cells. They're designed to bind to antigens on the surface of cancer cells, which are usually more abundant than on the surface of healthy cells. The use of monoclonal antibodies to treat cancer is a highly effective therapeutic option for both hematologic and solid cancers.
Market Dynamics
The statistical data by World Health Organization displays that cancer is the second biggest cause of mortality worldwide, accounting for 9.6 million fatalities in 2018, or one in every six deaths. The drastic surge in cancer patients and its treatment worldwide supplement the growth of the cancer monoclonal antibodies market. Pharmaceuticals and healthcare industries are significantly investing in the market. Moreover, rising investments in genomic research and development, advancements in target gene selection and genetic sequencing, and a greater demand for monoclonal antibodies' specificity to treat cancer are further paving the way for the market's growth. Policies and regulations regarding the mAbs production and approval, clinical trial failures, and high cost impede the market's development.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cancer monoclonal antibodies. The growth and trends of cancer monoclonal antibodies industry provide a holistic approach to this study.
Market Segmentation
This section of the cancer monoclonal antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Murine Antibodies
- Chimeric Antibodies
- Humanized Antibodies
- Others
By Medication Type
- Bevacizumab (Avastin)
- Rituximab (Rituxan)
- Trastuzumab (Herceptin)
- Cetuximab (Erbitux)
- Panitumumab (Vectibix)
- Others
By Application
- Breast Cancer
- Blood Cancer
- Liver Cancer
- Brain Cancer
- Colorectal Cancer
- Others
By End-User
- Hospitals And Clinics
- Pharmacies
- Research Laboratories
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Cancer Monoclonal Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Cancer Monoclonal Antibodies Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cancer monoclonal antibodies market include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.